Phaseline

Targets › PTH

PTH (Parathyroid hormone): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Metabolic and endocrine; next expected readout May 2027.

Peptide hormone secreted by parathyroid chief cells that acts as a primary endocrine regulator of extracellular calcium and phosphate homeostasis, acting primarily on bone and kidney to maintain serum calcium levels within a narrow range. Acts by binding and activating the G protein-coupled receptor PTH1R, engaging the receptor to activate G(s)-mediated cAMP/PKA signaling and G(q)-mediated PLC/PKC signaling. (UniProt, P01270)

Open in Phaseline: the race on PTH, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Extend BiosciencesEXT608
Modified parathyroid hormone attached to vitamin D to extend half-life
PTHPhase 2HypoparathyroidismMay 2027

Conditions

Hypoparathyroidism (1)

Modalities

small molecule (1)

Companies

Extend Biosciences (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.